Tech Company Financing Transactions
Allotera Therapeutics Funding Round
Allotera Therapeutics closed a $35 million investment round on 7/9/2026. Investors included Banc of California, BioGenerator and Lightchain.
Transaction Overview
Company Name
Announced On
7/9/2026
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$35,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4260 Forest Park Ave 100
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Website
Email Address
Not Recorded
Overview
Wugen, Inc. is a pivotal-stage American-born biotechnology company advancing the next generation of off-the-shelf cell therapies. Our allogeneic therapies are derived from healthy donor cells and are engineered to deliver robust anti-tumor activity. With our proprietary CAR-T platform, Wugen is addressing critical unmet needs in hematologic malignancies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kumar Srinivasan
Chief Medical Officer
Cherry Thomas
Chief Operating Officer
Ayman Kabakibi
Chief Scientific Officer
Matthew Cooper
Chief Technical Officer
Jim Faulkner
VP - Finance
Mark Lewis
VP - Operations
Jacqui Blem
VP - Operations
Ghee Kim
VP - Regulatory Affairs
Mayda Mercado
VP - Regulatory Affairs
Laura Simpson
Browse more venture capital transactions:
Prev: 7/9/2026: 23i venture capital transaction
Next: 7/9/2026: Grace Investment Machine venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs